2927 AFC-HD AMS Life Science Co.,Ltd. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

2927

TSE Standard

AFC-HD AMS Life Science Co.,Ltd.

841

JPY

-3

(-0.36%)

May 7, 3:30 pm JST

5.88

USD

May 7, 2:30 am EDT

Result

PTS

outside of trading hours

ー

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Aug, 2021	22,368	2,245	2,161	1,495	107.1	27.50	Oct 15, 2021	J-GAAP
Aug, 2022	23,024	1,015	1,343	735	52.3	30	Oct 14, 2022	J-GAAP
Aug, 2023	25,579	1,636	1,654	1,102	78.5	27.50	Oct 13, 2023	J-GAAP
Aug, 2024	30,185	1,916	1,921	1,252	89.2	30	Oct 15, 2024	J-GAAP
Aug, 2025 Guidance	31,100	2,200	2,200	1,320	93.9	32	Oct 15, 2024	J-GAAP
YoY	+3.0%	+14.8%	+14.5%	+5.4%	+5.3%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Aug, 2020	Oct 10, 2019	16,500	1,050	1,050	700	20	J-GAAP
	Apr 9, 2020	15,500	900	900	550	20	J-GAAP
Results	Oct 9, 2020	15,819	1,093	1,099	676	20	J-GAAP
Aug, 2021	Oct 9, 2020	Available in future release
	Jan 20, 2021
	Apr 5, 2021
	Jul 2, 2021
Results	Oct 15, 2021
Aug, 2022	Oct 15, 2021
	Nov 18, 2021
	Jan 14, 2022
	Apr 14, 2022
Results	Oct 14, 2022
Aug, 2023	Oct 14, 2022
	Feb 6, 2023
	Mar 14, 2023
	Jul 3, 2023
	Jul 14, 2023
Results	Oct 13, 2023
Aug, 2024	Oct 13, 2023
	Sep 17, 2024
Results	Oct 15, 2024
Aug, 2025	Oct 15, 2024	31,100	2,200	2,200	1,320	32	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Aug, 2000	1,785	－	Available in future release
Aug, 2001	2,722	+52.5
Aug, 2002	2,249	-17.4
Aug, 2003	3,269	+45.4
Aug, 2004	4,336	+32.6
Aug, 2005	5,955	+37.3
Aug, 2006	5,459	-8.3
Aug, 2007	6,952	+27.3
Aug, 2008	10,221	+47.0
Aug, 2009	12,813	+25.4
Aug, 2010	14,448	+12.8
Aug, 2011	14,653	+1.4
Aug, 2012	14,794	+1.0
Aug, 2013	14,366	-2.9
Aug, 2014	13,727	-4.4
Aug, 2015	14,415	+5.0
Aug, 2016	14,631	+1.5
Aug, 2017	15,141	+3.5
Aug, 2018	15,795	+4.3
Aug, 2019	16,252	+2.9
Aug, 2020	15,819	-2.7
Aug, 2021	22,368	+41.4
Aug, 2022	23,024	+2.9
Aug, 2023	25,579	+11.1
Aug, 2024	30,185	+18.0
Aug, 2025 Guidance	31,100	+3.0	2,200	+14.8	2,200	+14.5	93.9	+5.3

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Aug, 2023	25,579	1,636	6.40	8.64	2.81	0.65	78.5
Aug, 2024	30,185	1,916	6.35	9.26	2.84	0.69	89.2
Aug, 2025 Guidance	31,100	2,200	7.07	9.02	2.76	0.65	93.9

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	30,185	2,245	2,161	1,495	107.1
Fiscal Year	Aug, 2024	Aug, 2021	Aug, 2021	Aug, 2021	Aug, 2021

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar - Aug, 2022	11,822	562	701	428	30.5	15	Oct 14, 2022	J-GAAP
Mar - Aug, 2023	13,135	958	946	688	49.0	15	Oct 13, 2023	J-GAAP
Mar - Aug, 2024	15,643	893	861	611	43.5	15	Oct 15, 2024	J-GAAP
Mar - Aug, 2025 Guidance	14,486	906	868	439	31.2	16	Apr 14, 2025	J-GAAP
YoY	-7.4%	+1.5%	+0.8%	-28.2%	-28.3%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Aug, 2022	1,015	415	1,492	-1,077	1,159	10,257	27.46	J-GAAP
Aug, 2023	1,636	-1,081	865	-1,946	1,881	11,062	26.93	J-GAAP
Aug, 2024	1,916	-1,221	1,540	-2,761	2,232	12,070	25.66	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Sep - Feb, 2022	12,444	678	708	414	29.5	42.8	Apr 14, 2023	J-GAAP
Sep - Feb, 2023	14,542	1,023	1,060	641	45.8	55.2	Apr 15, 2024	J-GAAP
Sep - Feb, 2024	16,614	1,294	1,332	881	62.7	60.5	Apr 14, 2025	J-GAAP
YoY	+14.2%	+26.5%	+25.7%	+37.4%	+36.8%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Mar - May, 2023	6,251	376	377	268	19.1	6.0	Jul 14, 2023	J-GAAP
Jun - Aug, 2023	6,884	582	569	420	29.9	8.5	Oct 13, 2023	J-GAAP
Sep - Nov, 2023	6,786	478	489	318	22.8	7.0	Jan 12, 2024	J-GAAP
Dec - Feb, 2023	7,756	545	571	323	23.1	7.0	Apr 15, 2024	J-GAAP
Mar - May, 2024	7,802	472	454	281	20.1	6.0	Jul 16, 2024	J-GAAP
Jun - Aug, 2024	7,841	421	407	330	23.5	5.4	Oct 15, 2024	J-GAAP
Sep - Nov, 2024	8,189	650	704	460	32.7	7.9	Jan 14, 2025	J-GAAP
Dec - Feb, 2024	8,425	644	628	421	29.9	7.6	Apr 14, 2025	J-GAAP
YoY	+8.6%	+18.2%	+10.0%	+30.3%	+29.8%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar - May, 2020	3,781	-2.6	Available in future release
Jun - Aug, 2020	4,146	+2.8
Sep - Nov, 2020	4,637	+20.3
Dec - Feb, 2020	4,513	+11.7
Mar - May, 2021	5,345	+41.4
Jun - Aug, 2021	7,873	+89.9
Sep - Nov, 2021	5,461	+17.8
Dec - Feb, 2021	5,741	+27.2
Mar - May, 2022	5,511	+3.1
Jun - Aug, 2022	6,311	-19.8
Sep - Nov, 2022	5,686	+4.1
Dec - Feb, 2022	6,758	+17.7
Mar - May, 2023	6,251	+13.4
Jun - Aug, 2023	6,884	+9.1
Sep - Nov, 2023	6,786	+19.3
Dec - Feb, 2023	7,756	+14.8
Mar - May, 2024	7,802	+24.8
Jun - Aug, 2024	7,841	+13.9
Sep - Nov, 2024	8,189	+20.7
Dec - Feb, 2024	8,425	+8.6	644	+18.2	628	+10.0	29.9	+29.4

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	8,425	900	881	625	45.0
Fiscal Year	Feb, 2024	May, 2021	May, 2021	May, 2021	May, 2021

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Aug, 2022	884.53	33.2	37,348	12,414	7,880	1.38	Oct 14, 2022	J-GAAP
Aug, 2023	938.25	31.9	41,071	13,108	8,589	1.49	Oct 13, 2023	J-GAAP
Aug, 2024	990.10	29.6	47,030	13,924	9,415	1.64	Oct 15, 2024	J-GAAP
Sep - Feb, 2024	1,041.15	30.7	47,745	14,638	10,156	1.62	Apr 14, 2025	J-GAAP

AFC-HD AMS Life Science Co.,Ltd.(2927) Financial Results